TEDx 2019

Katerva Awards

BIO Fly-In 2019


April 27, 2019

TEDx Portland is an independently organized TED event. In its ninth consecutive year, it has a rich history of spreading ideas, sharing knowledge and building community in Portland.

Join DesignMedix founder, Dr. David Peyton and other thought provoking speakers for a day of showing how the power of ideas inspires us to re-calibrate adversity into prosperity.

View the video here, Dr. Peyton's talk begins at 59:45. 

April 15, 2019

DesignMedix, Inc. nominated as a finalist for the annual Katerva 2019 award in the Human Development category.

For the 8th year Katerva has been scouring the globe to identify the most promising sustainable disruptive innovations, the kind of innovation that makes our world a better place, and leads us towards sustainability.

April 17, 2019

Oregon Bioscience Association participated in the 2019 BIO Legislative Day Fly-In with two of our member companies, DesignMedix and RevMedx. Biotechnology Innovation Organization (BIO) had a strong turnout with representatives from over 41 states and more than 200 biotechnology and life science industry leaders from across the U.S. attended these meetings.



DesignMedix Inc. wins Portland Business Journal’s Manufacturer of the Year (1-10 employees)

November 12, 2018

By Denise Szott – Contributing writer for Portland Business Journal

The Portland company developed a drug to cure malaria that is easy and cheap to manufacture

Oregonians Lead Search On New Drug To Solve Malaria

by Kristian Foden-Vencil | OPB Oct. 18, 2018 1:52 p.m. | Updated: Oct. 23, 2018 6:49 a.m. | Portland, Ore.

Ten years ago, Portland State University chemistry professor David Peyton was troubled by news that the malaria drug Chloroquine was becoming less effective.

So he worked with his students to brainstorm possible fixes and then attended a tropical medicine conference in Miami.

Human trials begin for DesignMedix anti-malarial drug developed to overcome growing drug resistance

September 10, 2018

DesignMedix’s lead product, experimental anti-malaria medicine DM1157, has begun human clinical trials. DM1157, discovered at Portland State University (PSU) and developed by DesignMedix, was designed to overcome the serious issue of growing drug resistance among malaria medicines.

DesginMedix, Inc. received a green light from the FDA on its plan for Malaria drug DM1157 to begin Phase I clinical trials at Duke Clinical Research Institute, with sponsorship from the Nation Institutes of Health.

April 10, 2018

April 10, 2017

DesignMedix, Inc., a drug development company targeting drug resistant infectious diseases, has entered into an agreement with the National Institutes of Health (NIH) that will pave the for first-in-human clinical trials of DesignMedix's Malaria drug DM1157